Abstract
Several studies indicate that high oxidative stress is associated with various degenerative diseases, including tumors. The high levels of free radicals present in many patients derive from the chronic lack of antioxidants, caused by an increasingly poor and artificial diet. The study presented in this research, conducted on 50 male volunteers, carriers of Prostatic Carcinoma (PCa) at different stages of development and under current therapy, showed that the daily intake of antioxidants contained in two food supplements, Citozym (CIZ) and Propulzym (PRZ), induces a significant increase of the ratio free/total PSA and also a reduction of various clinical parameters, correlated with PCa. This result suggests a potential slowdown in the progression of the disease. This study was planned on the basis of a recent preliminary trial, that highlighted the positive activity of CIZ in a model of benign prostatic hypertrophy. Studies are in progress to identify the components present in these food supplements affecting biochemical signals, elements that underlie the ability of PCa to progress. This does not mean that the intake of antioxidants is a cure for PCa, but that a high undiagnosed oxidative stress, much less correct by the standard oncological approaches, contributes to the evolution of the tumor disease. In other words, current oncology focuses correctly on reducing the tumor mass, but does not intervene on the biological medium that produced it. This is why there is still a dramatic incidence of relapses.
Highlights
Prostatic Carcinoma (PCa) is recognized as one of the main medical problems facing the male population
This study was planned on the basis of a preliminary experimental trial that highlighted the positive activity of CIZ in a model of benign prostatic hypertrophy [6]
The adjuvant function exerted on the antitumor therapy, by the two antioxidants CYZ and PRZ, is evident for free and total PSA, whose values are reduced by 7% and in the ratio free/total PSA increased of about 4%
Summary
PCa is recognized as one of the main medical problems facing the male population. In Europe, it is by far the most frequent neoplasia, with an annual incidence of 214 cases per 1000 men for an estimated 2.6 million new cases each year, and the second leading cause of death by neoplasm. The free PSA shows a low diagnostic specificity and is poorly reliable to select clinically significant tumors For this reason, over the years it has been tried to improve the specificity of PSA with some of its variants such as the relationship between free and total PSA, which finds its rationale in the fact that neoplastic prostate cells produce less PSA in free form than to benign cells. Over the years it has been tried to improve the specificity of PSA with some of its variants such as the relationship between free and total PSA, which finds its rationale in the fact that neoplastic prostate cells produce less PSA in free form than to benign cells The evaluation of these two fractions of PSA, showed that alterations affecting free PSA are found mainly in benign prostatic hypertrophy, while alterations in the levels of linked PSA are often due to malignant diseases. Remember that there is no unanimity on the upper limit of normality, for example the National Health Service identifies the value 3.0 ng / mL, the Havard University sets normal limits proportional to age
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Clinical Oncology and Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
